Coencapsulation of Arsenic- and Platinum-based Drugs for Targeted Cancer Treatment

被引：68

作者：

Chen, Haimei ^{[1
]}

Pazicni, Samuel ^{[2
]}

Krett, Nancy L. ^{[3
]}

Ahn, Richard W. ^{[1
]}

Penner-Hahn, James E. ^{[2
]}

Rosen, Steven T. ^{[3
]}

O'Halloran, Thomas V. ^{[1
]}

机构：

[1] Northwestern Univ, Chem Life Proc Inst, Evanston, IL 60208 USA

[2] Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2009年 / 48卷 / 49期

关键词：

arsenic trioxide; cisplatin; coencapsulation; liposome; targeted delivery; CISPLATIN; TRIOXIDE; LIPOSOMES; COMPLEXES; ENCAPSULATION; NANOCAPSULES; RECEPTOR; ACID;

D O I：

10.1002/anie.200903655

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

(Figure Presented) Two In one: A novel strategy for efficiently coencapsulating both arsenic- and platinum-based drugs into 100 nm-scale liposomes (NBs) relies on the formation of PtIIAsIII adducts. This co-loaded system presents a robust platform for further modification with targeting ligands and affords a method of improving the therapeutic efficacy of anticancer agents. © 2009 Wiley-VCH Verlag GmbH & Co. KGaA.

引用

页码：9295 / 9299

页数：5

共 35 条

[1] Drug delivery systems: Entering the mainstream [J].

Allen, TM ;

Cullis, PR .

SCIENCE, 2004, 303 (5665) :1818-1822

[2]

Allen TM, 2002, CELL MOL BIOL LETT, V7, P889

[3] REACTIONS OF PLATINUM(II) AQUA COMPLEXES .1. MULTINUCLEAR (PT-195,N-15, AND P-13) NMR-STUDY OF REACTIONS BETWEEN THE CIS-DIAMMINEDIAQUAPLATINUM(II) CATION AND THE OXYGEN-DONOR LIGANDS HYDROXIDE, PERCHLORATE, NITRATE, SULFATE, PHOSPHATE, AND ACETATE [J].

APPLETON, TG ;

BERRY, RD ;

DAVIS, CA ;

HALL, JR ;

KIMLIN, HA .

INORGANIC CHEMISTRY, 1984, 23 (22) :3514-3521

[4] Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models [J].

Bandak, S ;

Goren, D ;

Horowitz, A ;

Tzemach, D ;

Gabizon, A .

ANTI-CANCER DRUGS, 1999, 10 (10) :911-920

[5] Endocytic mechanisms for targeted drug delivery [J].

Bareford, Lisa A. ;

Swaan, Peter W. .

ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (08) :748-758

[6] Arsenic compounds in the treatment of multiple myeloma: A new role for a historical remedy [J].

Berenson, James R. ;

Yeh, Howard S. .

CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (03) :192-198

[7] HYDROLYSIS PRODUCTS OF CISPLATIN - PKA DETERMINATIONS VIA [H-1, N-15] NMR-SPECTROSCOPY [J].

BERNERSPRICE, SJ ;

FRENKIEL, TA ;

FREY, U ;

RANFORD, JD ;

SADLER, PJ .

JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1992, (10) :789-791

[8] Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity [J].

Burger, KNJ ;

Staffhorst, RWHM ;

de Vijlder, HC ;

Velinova, MJ ;

Bomans, PH ;

Frederik, PM ;

de Kruijff, B .

NATURE MEDICINE, 2002, 8 (01) :81-84

[9] Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release [J].

Chen, Haimei ;

MacDonald, Robert C. ;

Li, Shuyou ;

Krett, Nancy L. ;

Rosen, Steven T. ;

O'Halloran, Thomas V. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (41) :13348-13349

[10] Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide [J].

Chen, Haimei ;

Ahn, Richard ;

Van den Bossche, Jeroen ;

Thompson, David H. ;

O'Halloran, Thomas V. .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) :1955-1963

← 1 2 3 4 →